We are excited to announce that Tubulis has dosed the first patient in its Phase I/IIa trial for TUB-030, an antibody-drug conjugate (ADC) targeting advanced solid tumors.

This is already the second drug candidate to reach the clinical stage within 1 year. The 5-STAR 1-01 clinical trial is expected to enroll up to 130 patients in the U.S. and Canada, with the dose optimization cohort focusing on selected major cancer indications.
TUB-030 is a next-generation ADC targeting 5T4, an antigen expressed in a variety of solid tumors. It was developed using Tubulis’ proprietary Tubutecan linker-payload platform, which enables sustained on-tumor payload delivery.
Big congratulations to the entire Tubulis team on another significant achievement! We are proud to support your mission to revolutionize cancer treatment with advanced ADCs.
More information in the press release under the following link
More about Tubulis